Sun Pharma, one of India’s leading pharmaceutical companies, has been a strong player in the global healthcare industry. With its focus on innovation, expansion in international markets, and a strong product pipeline, the company holds great potential for future growth. Sun Pharma Share Price on 4 March 2025 is 1,565.00 INR. This article will provide more details on Sun Pharma Share Price Target 2025, 2026 to 2030.
Sun Pharma Company Info
- Founder: Dilip Shanghvi
- Headquarters: Goregaon, Mumbai
- Number of employees: 43,000 (2024)
- Revenue: 44,520 crores INR (US$5.6 billion, 2023)
- Subsidiaries: Taro Pharmaceutical Industries Ltd
Sun Pharma Share Price Chart
Sun Pharma Share Price Details
- Today Open: 1,585.00
- Today High: 1,590.00
- Today Low: 1,556.00
- Mkt cap: 3.75LCr
- P/E ratio: 32.80
- Div yield: 0.99%
- 52-wk high: 1,960.35
- 52-wk low: 1,377.20
Sun Pharma Shareholding Pattern
- Promoters: 54.48%
- Foreign Institutions: 18.05%
- Mutual Funds: 12.24%
- Retails and others: 8.92%
- Domestic Institutions: 6.31%
Sun Pharma Share Price Target Tomorrow 2025, 2026 To 2030
- 2025 – ₹1965
- 2026 – ₹2050
- 2027 – ₹2175
- 2028 – ₹2315
- 2029 – ₹2460
- 2030 – ₹2590
Sun Pharma Share Price Target 2025
Sun Pharma share price target 2025 Expected target could be ₹1965. Sun Pharma, one of India’s leading pharmaceutical companies, has strong growth potential driven by several key factors. Here are five major elements that could influence its share price target for 2025:
1. Expansion in Global Markets
Sun Pharma is increasing its presence in international markets, including the U.S. and Europe. Growth in exports and regulatory approvals for new drugs can significantly boost its revenue and share price.
2. Strong Product Pipeline and Innovation
The company continues to invest in research and development (R&D) to introduce new medicines and generic drugs. Successful launches of innovative treatments can enhance its market position and profitability.
3. Rising Demand for Healthcare and Pharmaceuticals
With an aging population, increasing health awareness, and higher demand for medicines, Sun Pharma is well-placed to benefit from the growing healthcare sector, both in India and globally.
4. Government Policies and Drug Pricing Regulations
Supportive government policies, including incentives for pharmaceutical companies and favorable regulations, can drive Sun Pharma’s growth. However, price controls on essential medicines may impact profitability.
5. Strategic Acquisitions and Partnerships
Sun Pharma has a history of expanding through acquisitions and collaborations. Future mergers, partnerships, or investments in high-growth segments like biologics and specialty medicines can fuel further growth.
Sun Pharma Share Price Target 2030
Sun Pharma share price target 2030 Expected target could be ₹2590. While Sun Pharma has strong growth potential, several risks and challenges could impact its share price target for 2030. Here are five key concerns:
1. Regulatory and Compliance Risks
Pharmaceutical companies face strict regulations in global markets like the U.S. and Europe. Any failure to meet compliance standards, delays in drug approvals, or legal issues can negatively affect Sun Pharma’s reputation and stock performance.
2. Pricing Pressure and Government Policies
Price controls on essential medicines, both in India and abroad, can reduce profit margins. Governments may impose stricter pricing regulations, limiting Sun Pharma’s ability to set competitive drug prices.
3. Intense Market Competition
The pharmaceutical industry is highly competitive, with global giants and new entrants constantly introducing innovative drugs. Sun Pharma must continue investing in R&D to stay ahead and protect its market share.
4. Currency Fluctuations and Economic Conditions
Since Sun Pharma has significant international operations, fluctuations in foreign exchange rates can impact revenue and profitability. Economic slowdowns or trade restrictions in key markets may also affect business growth.
5. Legal and Patent Expiry Risks
Patent expirations for key drugs can lead to increased competition from generic drug manufacturers, reducing Sun Pharma’s revenue. Additionally, legal disputes over patents or intellectual property rights could pose financial risks.
Financials Statement Of Sun Pharma
| (INR) | 2024 | Y/Y change |
| Revenue | 484.97B | 10.51% |
| Operating expense | 265.35B | 14.07% |
| Net income | 95.76B | 13.01% |
| Net profit margin | 19.75 | 2.28% |
| Earnings per share | 41.69 | 15.97% |
| EBITDA | 128.76B | 10.51% |
| Effective tax rate | 13.03% | — |
Read Also:- SJVN Share Price Target Tomorrow 2025, 2026 To 2030